ArticleScientific reports2026
Isolation and characterization of probiotic candidates with antimicrobial and barrier-protective properties.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) in pathogens such as multidrug-resistant Salmonella Typhimurium and extended-spectrum β-lactamase (ESBL) Escherichia coli poses a growing threat to human, animal, and environmental health, yet effective non-antibiotic mitigation strategies remain limited. Here, we report the isolation and comprehensive characterization of three lactic acid bacteria from homemade cottage cheese, including Leuconostoc pseudomesenteroides MLS3, Lactococcus lactis MLS12, and Leuconostoc lactis MLS22 as next-generation probiotic candidates targeting these AMR pathogens. Whole-genome sequencing confirmed compact genomes (1.7-2.5 Mb) free of transferable resistance determinants and enriched in secondary metabolite biosynthetic clusters. All three strains survived gastrointestinal challenge conditions (≥ 6 log CFU/mL at pH 1.5, 2% bile salts, and 100 µg/mL lysozyme), exhibited strong mucosal adhesion parameters (auto-aggregation 30-33%, surface hydrophobicity 20-49%), and co-aggregated efficiently with both pathogens (27-64%). Live co-cultures and cell-free supernatants significantly inhibited S. Typhimurium and ESBL E. coli within 24 h, with electron microscopy revealing probiotic-induced structural disruption of pathogen cell integrity. Probiotic pretreatment extended Caenorhabditis elegans lifespan under Salmonella challenge (P < 0.001), and cell-free supernatants attenuated LPS-induced epithelial barrier permeability in chicken enteroids (P < 0.05) without affecting baseline barrier function. Together, these findings demonstrate that MLS3, MLS12, and MLS22 combine genomic safety, gastrointestinal resilience, direct antimicrobial potency, and epithelial barrier protection, supporting their potential as effective probiotics for AMR-associated applications in food safety and gut health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.